Latest News and Press Releases
Want to stay updated on the latest news?
-
July 13, 2019Announcement no. 14 BioPorto to redraw U.S. application for regulatory clearance of The NGAL Test™ for risk assessment for AKI in patients under the age of 22 with the intend to resubmit...
-
July 12, 2019 Announcement no. 13 NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING The Board of Directors hereby convenes an Extraordinary General Meeting of BioPorto A / S (the “Company”): ...
-
July 2, 2019Announcement no. 12 Adjustment of timeline for FDA decision regarding application for pediatric clinical use of The NGAL Test™ BioPorto A/S (“BioPorto”) announces today...
-
BioPorto A/S Managers' Transactions June 28, 2019Company announcement no. 11 Managers’ transactions BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of...
-
June 28, 2019Announcement no. 10 Changes in number of shares and votes Completion of share capital increase The Board of Directors of BioPorto A/S (“BioPorto”) decided on June...
-
June 26, 2019 News release BioPorto Appoints New Chief Medical Officer In preparation to fully leverage its biomarker technology, BioPorto further strengthens global leadership team ...
-
BioPorto A/S Other information disclosed according to the rules of the Exchange June 17, 2019 Announcement no. 9 Private placement fully subscribed With reference to company...
-
June 17, 2019Announcement no. 8 BioPorto A/S to Increase its Share Capital through a Cash...
-
May 15, 2019Announcement no. 7 BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation First test focused on risk assessment of Acute Kidney...
-
April 15, 2019Announcement no. 5 Grant of warrants Today, and in accordance with the company's Remuneration policy and guidelines for incentive-based remuneration and the...